Edmond Bernard
Edmond Bernard has a total of 53 co-authors. Here are the top co-authors by number of shared publications:
Alphaxard Manjurano
Mwanza Mwanza Region National Institute for Medical Research Mwanza Research Centre
2 shared publications- Rosemary Susan Lees
Vector biology Liverpool England L3 5QA Liverpool School of Tropical Medicine
2 shared publications - Rosine Zlanneu Wolie
Department of Natural Sciences (UFR-SN), Nangui Abrogoua University, Abidjan, Côte d’Ivoire
2 shared publications - Yvan Gaetan Fotso-Toguem
Microbiology and Parasitology Department Center for Research in Infectious Diseases Yaoundé Cameroon
2 shared publications Abdoulaye Diabate
Ouagadougou Centre Region Institut de Recherche en Sciences de la Sante
1 shared publicationAhmadi B Mpelepele
Vector Control Product Testing Unit Ifakara Morogoro Region Ifakara Health Institute
1 shared publication
Latest Publications
- Open Access
- 3 August 2026
- Published by F1000 Research Ltd in VeriXiv
Multi-site phenotypic characterisation of Kisumu colonies for comparison of insecticide susceptibility between testing centres
- 3 August 2026
- Published by F1000 Research Ltd in VeriXiv
Open AccessMulti-site phenotypic characterisation of Kisumu colonies for comparison of insecticide susceptibility between testing centres
- Open Access
Evaluation of dual-active ingredient long-lasting insecticidal nets against wild resistant malaria vectors in Tanzania: a series of experimental hut trials
The effectiveness of malaria vector control is increasingly threatened by widespread insecticide resistance, particularly to pyrethroids. In response, the World Health Organization recommends dual-active ingredients (dual-A.I.) insecticide-treated nets (ITNs) in resistant settings. This study evaluated the efficacy of several dual-A.I. ITNs in two experimental hut trial sites an area with high insecticide resistant malaria vectors in Tanzania with differing vector species composition and bionomics. Five ITNs were evaluated: a pyrethroid-only net (MAGNet®), three pyrethroid-piperonyl butoxide (PBO) nets (OlysetTM Plus, Veeralin®, and PermaNet® 3.0), one dual-A.I. net (Interceptor® G2; chlorfenapyr + alpha-cypermethrin), and an untreated control net. Mosquitoes were collected from huts, morphologically identified, and monitored for mortality up to 72 h. WHO cone and tunnel tests using susceptible An. gambiae s.s. were conducted for quality control, while field-collected mosquitoes were used for bio-efficacy monitoring. Molecular species identification was performed using PCR assays, and genomic DNA was extracted from An. funestus s.l. and An. gambiae s.l. collected from the trials. All ITNs met WHO bio-efficacy criteria in cone and tunnel tests. An. gambiae s.l. predominated in Mwagagala (77%) but was rare in Magu (4%), where An. funestus complex was dominant. In Magu, Interceptor® G2 and Veeralin® achieved significantly higher mortality than MAGNet® at 24 h (53% and 45% vs 24%) and 72 h (61% and 53% vs 24%). In contrast, no significant mortality differences were observed among ITNs in Mwagagala. High resistance intensity was detected in both vector groups (mortality An. funestus from Magu, the 4.3 kb-SV resistant genotype was fixed, while G454A-CYP9K1 resistance was highly prevalent (RR: 0.70– 1.00). Interceptor® G2 and Veeralin® outperformed the pyrethroid-only reference net against An. funestus complex but not against predominantly An. arabiensis populations.
Open AccessEvaluation of dual-active ingredient long-lasting insecticidal nets against wild resistant malaria vectors in Tanzania: a series of experimental hut trials
The effectiveness of malaria vector control is increasingly threatened by widespread insecticide resistance, particularly to pyrethroids. In response, the World Health Organization recommends dual-active ingredients (dual-A.I.) insecticide-treated nets (ITNs) in resistant settings. This study evaluated the efficacy of several dual-A.I. ITNs in two experimental hut trial sites an area with high insecticide resistant malaria vectors in Tanzania with differing vector species composition and bionomics. Five ITNs were evaluated: a pyrethroid-only net (MAGNet®), three pyrethroid-piperonyl butoxide (PBO) nets (OlysetTM Plus, Veeralin®, and PermaNet® 3.0), one dual-A.I. net (Interceptor® G2; chlorfenapyr + alpha-cypermethrin), and an untreated control net. Mosquitoes were collected from huts, morphologically identified, and monitored for mortality up to 72 h. WHO cone and tunnel tests using susceptible An. gambiae s.s. were conducted for quality control, while field-collected mosquitoes were used for bio-efficacy monitoring. Molecular species identification was performed using PCR assays, and genomic DNA was extracted from An. funestus s.l. and An. gambiae s.l. collected from the trials. All ITNs met WHO bio-efficacy criteria in cone and tunnel tests. An. gambiae s.l. predominated in Mwagagala (77%) but was rare in Magu (4%), where An. funestus complex was dominant. In Magu, Interceptor® G2 and Veeralin® achieved significantly higher mortality than MAGNet® at 24 h (53% and 45% vs 24%) and 72 h (61% and 53% vs 24%). In contrast, no significant mortality differences were observed among ITNs in Mwagagala. High resistance intensity was detected in both vector groups (mortality An. funestus from Magu, the 4.3 kb-SV resistant genotype was fixed, while G454A-CYP9K1 resistance was highly prevalent (RR: 0.70– 1.00). Interceptor® G2 and Veeralin® outperformed the pyrethroid-only reference net against An. funestus complex but not against predominantly An. arabiensis populations.